Literature DB >> 17876901

Fever as the only manifestation of hypersensitivity reactions associated with oxaliplatin in a patient with colorectal cancer Oxaliplatin-induced hypersensitivity reaction.

M Wasif Saif1, Shailja Roy, Leslie Ledbetter, Jennifer Madison, Kostas Syrigos.   

Abstract

Hypersensitivity reactions (HSR) to oxaliplatin in patients with colorectal cancer include facial flushing, erythema, pruritus, fever, tachycardia, dyspnea, tongue swelling, rash/hives, headache, chills, weakness, vomiting, burning sensations, dizziness, and edema. We report a patient with fever as the sole manifestation of initial HSR, review the literature and discuss the management of HSR. A 57-year-old female with T3N2M0 rectal adenocarcinoma received modified FOLFOX-6. She tolerated the first 8 cycles without any toxicities except grade 1 peripheral neuropathy and nausea. During 9th and 10th infusions, she developed fever to a maximum of 38.3 centigrade with stable hemodynamic status despite medications. During 11th infusion, she developed grade 3 HSR consisting of symptomatic bronchospasm, hypotension, nausea, vomiting, cough, and fever. On examination, she was pale, cyanotic, with a temperature of 38.8 centigrade, BP dropped to 95/43 mm Hg, pulse of 116/min and O(2) saturation of 88%-91%. She was hospitalized for management and recovered in 24 h. Fever alone is not a usual symptom of oxaliplatin HSR. It may be indicative that the patient may develop serious reactions subsequently, as did our patient who developed hypotension with the third challenge. Treatment and prevention consists of slowing the infusion rate, use of steroids and antagonists of Type 1 and 2 histamine receptor antagonists, whereas desensitization could help to provide the small number of patients who experience severe HSR with the ability to further receive an effective therapy for their colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17876901      PMCID: PMC4171312          DOI: 10.3748/wjg.v13.i39.5277

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  24 in total

1.  Idiosyncratic reaction after oxaliplatin infusion.

Authors:  D Santini; G Tonini; A Salerno; B Vincenzi; G Patti; F Battistoni; G Dicuonzo; R Labianca
Journal:  Ann Oncol       Date:  2001-01       Impact factor: 32.976

2.  Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients.

Authors:  Frédérique Maindrault-Goebel; Thierry André; Christophe Tournigand; Christophe Louvet; Nathalie Perez-Staub; Nora Zeghib; Aimery De Gramont
Journal:  Eur J Cancer       Date:  2005-09-09       Impact factor: 9.162

3.  Hypersensitivity reaction to cisplatin during chemoradiation therapy for gynecologic malignancy.

Authors:  Claude Koren; Rinat Yerushalmi; Alan Katz; Hana Malik; Aaron Sulkes; Eyal Fenig
Journal:  Am J Clin Oncol       Date:  2002-12       Impact factor: 2.339

4.  Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy.

Authors:  K M Zanotti; L A Rybicki; A W Kennedy; J L Belinson; K D Webster; B Kulp; G Peterson; M Markman
Journal:  J Clin Oncol       Date:  2001-06-15       Impact factor: 44.544

5.  Successful desensitization to oxaliplatin.

Authors:  Lydia Mis; Nishan H Fernando; Hurbert I Hurwitz; Michael A Morse
Journal:  Ann Pharmacother       Date:  2005-03-22       Impact factor: 3.154

6.  Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.

Authors:  Seth Hetherington; Arlene R Hughes; Michael Mosteller; Denise Shortino; Katherine L Baker; William Spreen; Eric Lai; Kirstie Davies; Abigail Handley; David J Dow; Mary E Fling; Michael Stocum; Clive Bowman; Linda M Thurmond; Allen D Roses
Journal:  Lancet       Date:  2002-03-30       Impact factor: 79.321

Review 7.  Hypersensitivity and idiosyncratic reactions to oxaliplatin.

Authors:  Rebecca R Thomas; Mary G Quinn; Barbara Schuler; Jean L Grem
Journal:  Cancer       Date:  2003-05-01       Impact factor: 6.860

8.  Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.

Authors:  Richard M Goldberg; Daniel J Sargent; Roscoe F Morton; Charles S Fuchs; Ramesh K Ramanathan; Stephen K Williamson; Brian P Findlay; Henry C Pitot; Steven Alberts
Journal:  J Clin Oncol       Date:  2006-07-20       Impact factor: 44.544

Review 9.  Hypersensitivity reactions to chemotherapeutic drugs.

Authors:  Gillian M Shepherd
Journal:  Clin Rev Allergy Immunol       Date:  2003-06       Impact factor: 8.667

10.  Hypersensitivity reactions related to oxaliplatin (OHP).

Authors:  G Brandi; M A Pantaleo; C Galli; A Falcone; A Antonuzzo; P Mordenti; M C Di Marco; G Biasco
Journal:  Br J Cancer       Date:  2003-08-04       Impact factor: 7.640

View more
  1 in total

1.  Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review.

Authors:  Nektaria Makrilia; Ekaterini Syrigou; Ioannis Kaklamanos; Leonidas Manolopoulos; Muhammad Wasif Saif
Journal:  Met Based Drugs       Date:  2010-09-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.